What question did this study set out to answer?

April 10, 2026Open Access

A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Key Points

This analysis aims to compare the efficacy of lenvatinib, atezolizumab plus bevacizumab, and sorafenib in treating unresectable hepatocellular carcinoma.
Conducted a network meta-analysis of available studies
Assessed overall survival as the primary outcome
Calculated hazard ratios (HRs) for treatment comparisons
Utilized SUCRA rankings to evaluate clinical trends
Overall survival rates were similar across all treatments
Hazard ratios showed no statistically significant differences
SUCRA rankings indicated a trend favoring atezolizumab plus bevacizumab

Abstract

Atezolizumab plus bevacizumab, lenvatinib, and sorafenib demonstrated similar therapeutic efficacy based on overall survival. Although the hazard ratios (HRs) were not statistically significant, the SUCRA ranking suggested a clinical trend favoring atezolizumab plus bevacizumab.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Ni Putu Sri Indrani Remitha

Udayana University

I Gede Aswin Parisya Sasmana

Udayana University

I Komang Wira Ananta Kusuma

Udayana University

Journals

Asian Pacific Journal of Cancer Prevention

Actions

Institutions

Udayana University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider